Ann: Change in substantial holding, page-66

From BL (with his permission)

"The article is complete BS. We don't generate any revenues because we don't yet have a commercial product. Our initial focus is on telehealth where our device acts as an aid to assist doctors to diagnose respiratory illness. Home diagnostic application (without the aid of doctors) is down the track. The large loss in the financials is due to the accounting valuation using Black and Scholes of incentive options and have no bearing on the cash burn or cash position which at >$12m is very healthy. With respect to 'a long way off commercialising', we anticipate regulatory approval around mid-year. Commercial deals should follow so 2nd half calendar 2017 revenues is expected should the FDA give RAP the nod. Besides, I'm not interested in daily movements of our SP. Fidelity have been scooping up shares held in loose hands. I'd be following the smart money. B"